简介:H.pylori相关性胃炎是消化内科的常见病、多发病。据报道,90%以上的慢性胃炎都有H.pylori感染[1]。临床主要表现为上腹胀满、嘈杂、纳呆和上腹隐痛等症状,病程缠绵,容易复发和癌变,治疗棘手。肖国辉教授,主任医师,硕士研究生导师。幼有异禀,
简介:摘要目的观察中西医结合在治疗消化性溃疡并幽门螺杆菌(H.pylori)感染患者中的临床效果。方法将60例消化性溃疡并H.pylori感染患者分为研究组与对照组,对照组患者采用常规四联疗法;研究组在对照组的基础上加以中药治疗;对比两组患者治疗效果以及不良反应的发生情况。结果治疗后,研究组患者临床治疗的总有效率显著高于对照组(P<0.05);且在治疗期间,两组患者均未出现严重不良反应(P>0.05)。结论中西结合在治疗消化性溃疡并H.pylori感染患者中具有良好的临床效果,能够有效提高患者治疗的有效率,值得推广。
简介:摘要:目的:探究健康体检者的H.pylori感染情况以及护理方法。方法:抽取体检的人员共300例,经过检查可得,H.pylori的感染者有86例,将其随机分为实验A组和实验B组,每组平均43例,分别使用H.pylori治疗以及H.pylori治疗结合护理。比较两组患者治疗后的成效,调查患者的满意情况。结果:实验A组患者治疗后的总有效性为81.4%,实验B组患者治疗后的总有效性为93%,则实验A组患者治疗后的有效性小于实验B组患者治疗后的有效性。实验A组患者的满意度评分低于实验B组的满意度评分。结论:对健康体检者的H.pylori感染进行治疗联合相应的护理服务,可促进患者的身体恢复,值得推崇。
简介:摘要目的探究并比较对幽门螺杆菌阳性小儿胃炎患儿应用含铋剂四联疗法与传统三联疗法治疗方式实施救治的临床治疗结果。方法选取我院接收诊治的幽门螺杆菌阳性小儿胃炎患儿48例作为研究样本,随机分为对照组及观察组,对照组应用传统三联疗法,即奥美拉唑、克拉霉素、阿莫西林实施救治,观察组采用含铋剂四联疗法,即埃索美拉唑、克拉霉素、果胶铋、阿莫西林实施救治。观察并比较两组临床治疗结果。结果观察组患儿临床治疗有效率相较于对照组对应数值,提升趋势显著(P<0.05)。结论对幽门螺杆菌阳性小儿胃炎患儿采用含铋剂四联疗法埃索美拉唑、克拉霉素、果胶铋、阿莫西林实施救治,相较传统三联疗法于奥美拉唑、克拉霉素、阿莫西林治疗方式,临床治疗结果显著,对患儿临床治疗有效率的提升具有积极作用。
简介:LongbeforethediscoveryofHelicobacterpylori,thereweremanyexcellentobservationalstudiesthatdocumenteddifferencesinthepatternsofgastroduodenaldisease.Itwasclearthatinthedevelopingworld,gastriculcerandgastriccancerweremorecommonthaninthedevelopedworldwhereduodenalulcerpredominated.Thiscorrelatedwiththedistributionofgastritisinduodenalulcerpatientswheretheinflammationwasantralpredominantwhileingastriculcerpatientsthegastritiswasmoreevenlydistributedthroughthestomach.Gastriculcersusuallyappearedinafairlyrestricteddistributioninthestomachneartheangulusandclosetothetransitionalzonebetweenantrumandbodymucosa.Asasocietydevelopedsothesepatternsofdiseasechanged.
简介:ToinvestigatetheprotectiveeffectofdecoctionofliaoweiongastricmucosaofH.pyloriassociatedchronicatrophicgastritisinrats.TheH.pyloriassociatedchronicatrophicgastritismodelswereinducedwithsodiumdeoxycholate,sodiumsalicylate,ethanol,andculturebrothofH.pylori.ProtectiveeffectofdecoctionofliaoweiongastricmucosaofH.pyloriassociatedchronicatrophicgastritiswasobservedquantitatively.
简介:AbstractBismuth-containing quadruple therapy (BQT) has long been recommended for Helicobacter pylori (H. pylori) eradication in China. Meanwhile, in the latest national consensus in China, dual therapy (DT) comprising an acid suppressor and amoxicillin has also been recommended. In recent years, the eradication rate of H. pylori has reached >90% using DT, which has been used not only as a first-line treatment but also as a rescue treatment. Compared with BQT, DT has great potential for H. pylori eradication; however, it has some limitations. This review summarizes the development of DT and its application in H. pylori eradication. The H. pylori eradication rates of DT were comparable to or even higher than those of BQT or standard triple therapy, especially in the first-line treatment. The incidence of adverse events associated with DT was lower than that with other therapies. Furthermore, there were no significant differences in the effects of dual and quadruple therapies on gastrointestinal microecology. In the short term, H. pylori eradication causes certain fluctuations in the gastrointestinal microbiota; however, in the long term, the gastrointestinal microbiota eventually returns to its normal state. In the penicillin-naïve population, patients receiving DT have a high eradiation rate, better compliance, lower incidence of adverse reactions, and lower primary and secondary resistance to amoxicillin. These findings suggest the safety, efficacy, and potential of DT for H. pylori eradication.
简介:AbstractThe main challenge in the field of Helicobacter pylori (H. pylori) infection is antibiotic resistance, which influences the efficacy of eradication regimens. Bismuth-containing quadruple therapy has been confirmed as an effective regimen for eradicating H. pylori, especially in strains with antibiotic resistance. High-dose proton-pump inhibitor-amoxicillin dual therapy could decrease the use of unnecessary antibiotics, which is a promising alternative approach. Adjuvant therapy (specific probiotic or vitamin) also showed good results, although more evidence is needed. Novel anti-H. pylori drugs are needed, and the establishment of the H. pylori database is an effective way to acknowledge the real-time information of H. pylori management. This review provides the recent progress of H. pylori treatment, and further studies are needed to address the role of different regimens in improving H. pylori eradication rate, especially in strains with antibiotics resistance.
简介:EversinceHelicobacterpylori(H.pylori)wasrecognizedasaninfectiouscauseofgastriccancer,therehasbeenincreasinginterestinexaminingitspotentialroleincolorectalcarcinogenesis.Datafromcasecontrolandcross-sectionalstudies,mostlyrelyingonhospital-basedsamples,andseveralmeta-analyseshaveshownapositivestatisticalrelationshipbetweenH.pyloriinfectionandcolorectalneoplasia.However,thepossibilityexiststhattheresultshavebeeninfluencedbybias,includingtheimproperselectionofpatientsanddisparitieswithrespecttopotentialconfounders.Whiletheevidencefallsshortofadefinitivecausallink,itappearsthatinfectionwithH.pylori/H.pylori-relatedgastritisisassociatedwithanincreased,althoughmodest,riskofcolorectaladenomaandcancer.Thepathogenicmechanismsresponsibleforthisassociationremainuncertain.H.pylorihasbeendetectedincolorectalmalignanttissues;however,thepossibilitythatH.pyloriisadirectactivatorofcoloniccarcinogenesisremainspurelyhypothetical.Ontheotherhand,experimentaldatahaveindicatedaseriesofpotentialoncogenicinteractionsbetweenthesebacteriaandcolorectalmucosa,includinginductionandperpetuationofinflammatoryresponses,alterationofgutmicrofloraandreleaseoftoxinsand/orhormonalmediators,suchasgastrin,whichmaycontributetotumorformation.
简介:CLINICALANDEXPERIMENTALSTUDYOFKILLINGEFFECTONHELICOBACTERPYLORICLINICALANDEXPERIMENTALSTUDYOFKILLINGEFFECTONHELICOBACTERPYLOR...
简介:Overthepastseveralyears,theseverityofHelicobacterpylori(H.pylori)infectionshasnotsignificantlydiminished.Aftersuccessfuleradication,theannualH.pylorirecurrencerateisapproximately13%duetooralH.pyloriinfection.EstablishedclinicaldiagnostictechniquesdonotidentifyanoraletiologicbasisofH.pyloripriortogastricinfection.TherehasbeendisagreementastowhetheroralinfectionofH.pyloriexistsornot,withnodefiniteconclusion.Inmedicalpractice,negativeresultswiththeureabreathtestsuggestthatthestomachinfectionofH.pyloriiscuredinthesepatients.Infact,patientscanpresentnegativeureabreathtestresultsandyetexhibitH.pyloriinfectionduetooralinfection.ThepresentpaperprovidesevidencethatH.pylorioralinfectionisnonethelesspresent,andtheoralcavityrepresentsasecondarysiteforH.pyloricolonization.
简介:AbstractBackground:Helicobacter pylori (HP) has been considered to be one of the primary causes of gastric mucosa-associated lymphoid tissue (MALT) lymphoma since 1993. Low-grade gastric MALT lymphoma with HP is widely treated with HP eradication therapy, according to each specific clinical situation. However, several studies and guidelines indicate that the modified HP eradication therapy is also valid for HP-negative gastric MALT lymphoma. The aim of this study was to perform a meta-analysis of the clinical efficacy of the modified HP eradication therapy for gastric MALT lymphoma without HP.Methods:We searched studies that reported the response rate of the modified HP eradication therapy regimen for gastric MALT lymphoma without HP by using PubMed, Medline, and Ebsco from January 1971 until February 2019. All statistical analyses were carried out using R 3.5.3 (Mathsoft Company, Cambridge, MA, USA). The pooled response rate was expressed as a decimal. The heterogeneity test was performed using the I-squared (I2) statistic.Results:A total of 14 studies were selected with a total of 148 patients with HP-negative gastric MALT lymphoma. The overall pooled response rate was 0.38 (95% confidence interval [CI]: 0.29-0.47). The combined estimate is I2 = 57% (P < 0.01). The study subjects were categorized by factors (area of patients). The pooled response rate of the sub-groups (Korea, Japan, China, and Western countries) was 0.63 (95% CI: 0.50-0.76), 0.16 (95% CI: 0.05-0.30), 0.38 (95% CI: 0.20-0.55), and 0.57 (95% CI: 0.08-1.00). The response rate showed that the modified HP eradication therapy was effective for patients with HP-negative gastric MALT lymphoma, especially in Korea and Western countries.Conclusion:Therefore, the modified HP eradication therapy can be considered an optional therapy for patients with low-grade HP-negative gastric MALT lymphoma. However, several limitations were revealed in the meta-analysis. Further systematic reviews and research are required.
简介:脱发areata是头发滤泡的疾病,与支持自体免疫的病原学的充分证据。脱发areata经常与象干癣和地衣planus那样的皮肤表明与调停免疫者的疾病被联系,或没有象自体免疫的甲状腺炎和自发的thrombocytopenic紫癜病那样的皮肤表明。Helicobacterpylori(H。pylori)感染在约50%世界人口是在场的并且包括自体免疫的甲状腺炎,自发的thrombocytopenic紫癜病,和干癣与许多调停免疫者的额外消化的混乱被联系了。有头皮和胡子的脱发areata的8瞬间历史的一个43年的老人的一个盒子被介绍。病人被一个皮肤学家正在对待并且有精神病学的支持,没有任何改进。他有消化不良的历史,脲呼吸测试证实了H。pylori感染。病人在H以后从脱发areata走进宽恕。pylori根除。如果如此的一个协会被为这个目的设计的流行病学的研究证实,新治疗学的选择能为这些病人是可得到的,特别在区域在哪儿有H的感染。pylori是高度流行的。
简介:AIM:ToverifythemethylationstatusofCDH1,DAPK,COX2,hMLH1andCDKN2AgenesandtoevaluatetheirassociationwithHelicobacterpylori(H.pylori)-cagA+andEpsteinBarrvirus(EBV)infectionsingastricadenocarcinomas.METHODS:Methylation-specificPCR(MSP)assaywasperformedin89primarygastriccarcinomas(intestinalanddiffusetypes).Microsatelliteinstability(MSI)analysiswasperformedusingtheBAT26primersetandPCRproductswereanalyzedwiththeABIPRISM3100GeneticAnalyzerusingG...